The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes.

This article focuses on the investigation of GNE-987, a novel proteolysis-targeting chimera (PROTAC) molecule, as a potential therapeutic agent for T-cell acute lymphoblastic leukemia (T-ALL). GNE-987 induces degradation of bromodomain and extraterminal (BET) proteins, particularly BRD4, via the E3 ubiquitin ligase Von Hippel-Lindau (VHL), leading to inhibited proliferation and increased apoptosis of T-ALL cells both in vitro and in vivo. The study further identifies that GNE-987 suppresses the expression of super-enhancer (SE)-associated oncogenes, notably lymphoblastic leukemia 1 (LCK), which plays a critical role in T-ALL progression. These findings suggest that GNE-987, through VHL-mediated BET protein degradation and downregulation of SE-related genes like LCK, holds promise as a novel candidate drug for T-ALL treatment.